戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 le to conversion to glycal 22 via the chloro acetonide.
2  effect on the cytotoxicity of triamcinolone acetonide.
3 olenic acid, 11-HLA) from (R)-glyceraldehyde acetonide.
4 e alone or in combination with triamcinolone acetonide.
5 ghtly long-lasting effect than triamcinolone acetonide.
6 roids such as dexamethasone and fluocinolone acetonide.
7  who were treated with inhaled triamcinolone acetonide (100 microg per puff).
8 thiophene, subsequent generation of the keto acetonide 12 followed by its Meerwein-Ponndorf-Verley re
9 emonstrated that panaxytriol and panaxytriol acetonide (12) moderately suppress tumor growth with lit
10 bizumab, 5386 bevacizumab, 935 triamcinolone acetonide, 121 pegaptanib sodium) were reviewed for 2465
11 duction of the ester and by formation of the acetonides 13bcd.
12 RPE-19 cells after exposure to triamcinolone acetonide (200 microg/mL) alone without the vehicle was
13       The R28 cells exposed to triamcinolone acetonide (200 microg/mL) without the vehicle also had a
14 per injection was 2 in 935 for triamcinolone acetonide, 3 in 9453 for ranibizumab, and 4 in 5386 for
15 Patients received intravitreal triamcinolone acetonide (32 eyes) or intravitreal bevacizumab (32 eyes
16 Patients received intravitreal triamcinolone acetonide (32 eyes) or intravitreal bevacizumab (32 eyes
17 perones in the presence of [3H]triamcinolone acetonide ([3H]TA), which binds to the receptor as GR.hs
18 riod of treatment with inhaled triamcinolone acetonide (400 microg twice per day).
19              They used inhaled triamcinolone acetonide, 600 mcg, or placebo, twice daily.
20 d by ester reduction and by formation of the acetonides 7bc.
21    Subjects were stabilized on triamcinolane acetonide (800 microg daily) and then enrolled in a 2-wk
22 synthesis of orthogonally protected Fmoc-Dyp-acetonide (9) and of several Fmoc-d-Hot horizontal lineT
23 18) derived from N-Boc-L-serine methyl ester acetonide (9), affording two novel ceramide analogues, (
24 in fact, engagement of the C9-C10 diol as an acetonide actually leads to notably enhanced cytotoxicit
25                                  Cyanohydrin acetonide alkylations were used to assemble the carbon s
26 re effective than intravitreal triamcinolone acetonide alone.
27 therapy with moderate doses of triamcinolone acetonide, an anti-inflammatory glucocorticoid, greatly
28 only in substrates that contain both a trans-acetonide and a tertiary amide substituent at C2.
29  of a 1,2-acetonide in the presence of a 1,3-acetonide and an (E)-selective olefination of an unstabl
30                                   Removal of acetonide and benzyl protecting groups afforded pure tri
31 I)-catalyzed reactions of (R)-glyceraldehyde acetonide and dibenzylamine with terminal alkynes provid
32 proved in 15 patients by using triamcinolone acetonide and in the remaining 15 patients by using infr
33 ds (budesonide, dexamethasone, triamcinolone acetonide, and dexamethasone acetate) ranged from 0.2 to
34 , chemical transformation into ecdysone 2, 3-acetonide, and mass spectrometry.
35 articles, blank nanoparticles, triamcinolone acetonide, and PBS groups following subconjunctival inje
36 ps (43% overall yield) from D-glyceraldehyde acetonide, and the cyclopentenone (+)-14, prepared in on
37 asone, mometasone furoate, and triamcinolone acetonide are pharmaceutical mainstays to treat chronic
38                         Using glyceraldehyde acetonide as a chiral-pool precursor, an enantioselectiv
39 ds; intralesional injection of triamcinolone acetonide at the ulcer margin; topical cromolyn sodium;
40 coids (triamcinolone acetonide, fluocinolone acetonide, clobetasol propionate, and fluticasone propio
41 ed crystallinity compared to their five-ring acetonide counterparts.
42                 The effects of triamcinolone acetonide cream 0.025% were assessed based on gene expre
43                                          The acetonide deprotection protocol described herein is expe
44  a high yielding, acid-mediated simultaneous acetonide deprotection-dithiane removal-ketalization pro
45  of DFT calculations, and the preparation of acetonide derivative 7a.
46 lute stereochemistry was determined on a bis-acetonide derivative using the variable temperature Mosh
47 adducts were confirmed by NMR analysis of 12 acetonide derivatives prepared from the corresponding 5,
48            Mass spectrometric analysis after acetonide derivatization also revealed that ester format
49 cycloaddition of cyclopent-2-en-1-one to the acetonide derived from enantiomerically pure and enzymat
50 ch has an altered affinity for triamcinolone acetonide, dexamethasone, and corticosterone.
51 tudy compared computer-modeled triamcinolone acetonide diffusion after posterior sub-Tenon's injectio
52         Treatment with topical triamcinolone acetonide dramatically reduced pathology but increased v
53 easible to construct a nontoxic fluocinolone acetonide drug delivery device that reproducibly release
54                             The fluocinolone acetonide drug pellet can dislocate spontaneously from t
55 beclomethasone dipropionate or triamcinolone acetonide during a 2-wk, single-blind, run-in period wer
56 rticular injection of 40 mg of triamcinolone acetonide every 3 months on progression of cartilage los
57 c application of glucocorticoid fluocinolone acetonide (FA).
58   To investigate the effects of fluocinolone acetonide (FAc) on the progression to proliferative diab
59 our synthetic glucocorticoids (triamcinolone acetonide, fluocinolone acetonide, clobetasol propionate
60                   Intravitreal triamcinolone acetonide followed by laser may be more effective than i
61  suspension releasing 5-FU and triamcinolone acetonide for 1 month.
62 200 microg/mL concentration of triamcinolone acetonide for 2, 6, and 24 hours.
63 mical modifications, including methanolysis, acetonide formation, and application of the modified Mos
64 o-step NMO-promoted osmylations bracketed by acetonide formation, and wholesale deprotection.
65 predicts efficient delivery of triamcinolone acetonide from the posterior sub-Tenon's space to the ex
66 protection of both terminal and internal N,0-acetonide functionalities.
67 o a cytosine aldehyde protected as the 2',3'-acetonide gave predominately the 5'R isomer, while phosp
68                         In the triamcinolone acetonide group, 12 months after surgery the amplitude o
69                             D-Glyceraldehyde acetonide has been used as the starting point for access
70 verse event associated with the fluocinolone acetonide implant (FAI), but no data are available regar
71               Sustained-release fluocinolone acetonide implant (Retisert) dissociation is a common oc
72  Twenty-seven sustained-release fluocinolone acetonide implant (Retisert) exchange or removal surgeri
73 7 consecutive sustained-release fluocinolone acetonide implant (Retisert) exchanges or removals betwe
74              Visual outcomes of fluocinolone acetonide implant and systemic treatment for intermediat
75 s with uveitis treated with the fluocinolone acetonide implant or standard systemic therapy.
76 surgically placed intravitreous fluocinolone acetonide implant or systemic corticosteroids supplement
77  that 75% of eyes receiving the fluocinolone acetonide implant required intraocular pressure (IOP) lo
78      These results suggest that fluocinolone acetonide implant therapy is associated with a clinicall
79                                 Fluocinolone acetonide implant therapy was associated with a greater
80                                 Fluocinolone acetonide implant therapy was reasonably cost-effective
81 munosuppression or intravitreal fluocinolone acetonide implant therapy.
82 rognosis with both systemic and fluocinolone acetonide implant treatment.
83 omized clinical trial comparing fluocinolone acetonide implant vs systemic corticosteroids and immuno
84 sociation between intravitreous fluocinolone acetonide implant vs systemic therapy and long-term visu
85  York, USA), a nonbiodegradable fluocinolone acetonide implant, was approved for use in noninfectious
86 than time to exchange of intact fluocinolone acetonide implants (70.5 vs 44.9 months; P < .001).
87 ] (aHR, 2.58); and prior use of fluocinolone acetonide implants (aHR, 9.75).
88                                 Fluocinolone acetonide implants can be considered, but have a high ri
89 mend that patients treated with fluocinolone acetonide implants receive frequent IOP monitoring and r
90 rds of 224 patients in whom 407 fluocinolone acetonide implants were placed by either of 2 surgeons b
91                 Of 77 exchanged fluocinolone acetonide implants without dislocated pellets, 11 (14.2%
92 omized to receive intravitreous fluocinolone acetonide implants.
93 vice that reproducibly releases fluocinolone acetonide in a linear manner over an extended period.
94 y scale (DRSS) grade during the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) A and B Phase
95 l injections of bevacizumab or triamcinolone acetonide in patients with macular edema and cataract is
96 ctions are a selective deprotection of a 1,2-acetonide in the presence of a 1,3-acetonide and an (E)-
97 tone to prepare 2,2-dimethyl-1,3-dioxolanes (acetonides) in good to excellent yields.
98                   In contrast, triamcinolone acetonide-induced luciferase activity was maximal at a d
99 ng suprachoroidal injection of triamcinolone acetonide injectable suspension (CLS-TA), in eyes with m
100    Intraoperative intravitreal triamcinolone acetonide injection induces earlier and marked exudative
101                   Intravitreal triamcinolone acetonide injection therapy, in particular the 4-mg dose
102 1, 2, 3, 4, and 8 weeks) after triamcinolone acetonide injection, with 6 controls without injection.
103 cizumab injections, 35 (44.9%) triamcinolone acetonide injections, and 5 (6.4%) a dexamethasone impla
104 neficial treatment effects for triamcinolone acetonide, interferon alpha-2a, and supplemental oxygen;
105                               A fluocinolone acetonide intravitreal implant (Retisert) was implanted
106                             The fluocinolone acetonide intravitreal implant was approved by the Unite
107                                 Fluocinolone acetonide intravitreal implants are an effective therapy
108                                Triamcinolone acetonide is toxic to proliferating cells of retinal ori
109 kness (CRT) after intravitreal triamcinolone acetonide (IVT) injection for macular edema secondary to
110                   Intravitreal triamcinolone acetonide (IVTA) is an effective treatment for recalcitr
111 Study showed that intravitreal triamcinolone acetonide (IVTA) is effective at reducing macular edema
112        In 3 eyes, intravitreal triamcinolone acetonide (IVTA) was injected within 8 weeks prior to th
113 iodistribution and kinetics of triamcinolone acetonide, labeled with 11C, formulated and nasally admi
114 ior sub-Tenon's injection with triamcinolone acetonide levels in experimental undiluted vitreous and
115 eoretical model predicted that triamcinolone acetonide levels in systemic blood, vitreous, and choroi
116 such as trans-retinoic acid and fluocinolone acetonide, markedly inhibit both 12-O-tetradecanoylphorb
117 llen joints were injected with triamcinolone acetonide (maximum dosage 80 mg per month).
118                   Intravitreal triamcinolone acetonide may be more effective than laser.
119                            Hydrolysis of the acetonide moiety of 41, followed by oxidative cleavage o
120  injections of corticosteroid (triamcinolone acetonide [n = 16] or triamcinolone hexacetonide [n = 7]
121 ed 4 weeks after intramuscular triamcinolone acetonide: normalization of (1) symptoms (Asthma Control
122 resent method was also extended to deprotect acetonides obtained from 1,2-, and 1,3-terminal diols.
123 zolide 11b which, upon coupling with 2',3'-O-acetonide of AMP, afforded the acetonide of benzamide ad
124  with 2',3'-O-acetonide of AMP, afforded the acetonide of benzamide adenine dinucleotide (15) in 94%
125                                The tricyclic acetonide of the dipeptide d-Hot horizontal lineTap is r
126                                          The acetonide of the protected amino acid cis-dihydroxyproli
127 ted cyclobutane was synthesized from the bis(acetonide) of d-glucose using dicyclopentadienylzirconiu
128 M peeling assisted with either triamcinolone acetonide or infracyanine green staining improves visual
129 al growth factor, intravitreal triamcinolone acetonide, or a combination of these therapies.
130                   Intravitreal triamcinolone acetonide, pars plana vitrectomy, oral protein kinase C
131 cyclization reaction taking advantage of the acetonide pendant group.
132 he addition of vinyllithium reagent 7 to the acetonide-protected aldehyde 8 to access the carbon back
133 ohex-2-ene-1-one (3) has been developed from acetonide-protected meso-1,2-dihydrocatechol derivative
134 diol-based subunits were prepared from their acetonide-protected precursors (1a-4a).
135            A lithium enolate derived from an acetonide-protected pyroglutaminol undergoes a highly se
136 ME2 and 2-methoxyestradiol-15 alpha,16 alpha-acetonide, provided 29.4% and 26.7% inhibition of tumor
137 age of 1.6 posterior sub-Tenon triamcinolone acetonide (PSTA) injections in the 12 months preceding i
138 LH/HWE ester homologation as well as a novel acetonide rearrangement/glycal formation cascade.
139                                 Fluocinolone acetonide slow release implant (Iluvien(R)) was approved
140                       However, triamcinolone acetonide staining is associated with an increase of fER
141 ssignment into 2 groups: 40-mg triamcinolone acetonide subacromial CSI versus 6 sessions of manual ph
142 conjunctival injection of 2 mg triamcinolone acetonide (TA) alone.
143 with the potent glucocorticoid triamcinolone acetonide (TA) and a fragment of the small heterodimer p
144 ansscleral drug delivery using triamcinolone acetonide (TA) as a model drug.
145 safety and pharmacodynamics of triamcinolone acetonide (TA) delivered by this technique.
146 GR activated by aldosterone or triamcinolone acetonide (TA) leads to significant transactivation of t
147 ugate of mitomycin C (MMC) and triamcinolone acetonide (TA) was synthesized using glutaric acid as a
148 examethasone (Dex), IL-10, and triamcinolone acetonide (TA) were used to antagonize proinflammatory s
149 nts-prednisolone acetate (PA), triamcinolone acetonide (TA), and lipid-based artificial tears (LBAT)-
150  and NONSA after intramuscular triamcinolone acetonide (TA), and to identify predictors of a corticos
151 00 microM CoCl(2), 1 microg/mL triamcinolone acetonide (TA), or both.
152 GR) and c-jun transcription in triamcinolone acetonide (TA)-treated AtT-20 cells.
153 electron-capture properties of triamcinolone acetonide (TAA) fatty acid conjugates were exploited for
154                                Triamcinolone acetonide (TAA) is an anti-inflammatory steroid used for
155   Intra-articular administered triamcinolone acetonide (TAA) is one of the drug treatments employed t
156 g, H: 1,540 microg per day and triamcinolone acetonide (TAA) L: 400 microg, M: 800 microg, H: 1,600 m
157  the C21 acetate derivative of triamcinolone acetonide (TAA) under methane chemical ionization mass s
158  to quantify the low levels of triamcinolone acetonide (TACA) in porcine plasma following suprachoroi
159                                Triamcinolone acetonide, the most commonly used intravitreal corticost
160 olipid analogues from D-mannitol 1,2:5,6-bis-acetonide to give two 1,1-difluorodeoxy analogues of (2R
161 a subconjunctival injection of triamcinolone acetonide to one eye.
162 ncapsulating the model steroid triamcinolone acetonide (Tr-A) were implanted subcutaneously in rats b
163 was observed in 4 intravitreal triamcinolone acetonide-treated patients (12%).
164 ented in 22 (69%) intravitreal triamcinolone acetonide-treated vs 11 (34%) intravitreal bevacizumab-t
165 In summary, the use of inhaled triamcinolone acetonide was associated with loss of BMD at the femoral
166              Carbon-11-labeled triamcinolone acetonide was formulated as the commercial product, and
167 th the vehicle alone, in which triamcinolone acetonide was suspended.
168 e P-450 3A (CYP3A) inducer] or triamcinolone acetonide (weak CYP3A inducer) produced dose-dependent i
169 derate potency steroids such as fluocinolone acetonide were inactive.
170  of a synthetic corticosteroid, fluocinolone acetonide, were constructed.
171 ma in response to intravitreal triamcinolone acetonide will be reviewed.
172 ve Suprachoroidal Injection of Triamcinolone Acetonide with Intravitreal Aflibercept in Subjects with
173 laser, or 4 mg of intravitreal triamcinolone acetonide with prompt laser.
174 he R28 cells were treated with triamcinolone acetonide with vehicle (200 microg/mL) for 24 hours (P <
175 nd R28 cells after exposure to triamcinolone acetonide with vehicle 200 microg/mL for 24 hours was 70
176                                Triamcinolone acetonide with vehicle caused a greater reduction in cel
177 9 cells when treated with both triamcinolone acetonide, with or without the vehicle at a concentratio
178 erwent periocular injection of triamcinolone acetonide, with resolution of the subretinal fluid.
179 ase activity when treated with triamcinolone acetonide without the vehicle at any of the doses, but t

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top